Boston-based startup RADiCAIT is excited to rock the stage at TechCrunch Disrupt 2025. It has secured a place as a Top 20 finalist in the Startup Battlefield. The company is focused on using artificial intelligence to make diagnostic imaging more affordable and accessible. Earlier this month, RADiCAIT released a new $5 million funding round. This investment will help it complete its clinical trials and continue developing its technology, which is among the country’s most innovative.
In 2021, the University of Oxford’s Artificial Intelligence Lab created a generative deep neural network that was the basis for RADiCAIT’s technology. This state-of-the-art method merges different models together, enabling medical experts to review an all-encompassing final picture. This innovative approach makes it easier to convert one form of biological data into another, speeding up the diagnostic process.
Regent Lee, co-founder and chief medical information officer of RADiCAIT, was the key driver in creating our foundational model. This model underpins the company’s cutting edge technology. The innovation has already garnered comparisons to Google DeepMind’s AlphaFold, an AI system that revolutionized protein structure prediction. Similar to AlphaFold, RADiCAIT’s innovation links different physical phenomena, converting anatomical structures into biological functions.
RADiCAIT is in clinical pilots now for testing RADiCAIT for lung cancer. Additionally, they’re partnering with large health systems such as Mass General Brigham and UCSF Health. Moreover, the startup hopes to launch clinical pilots and trials for colorectal cancer and lymphoma uses. The innovative company hopes to render PET scans unnecessary for diagnostics, staging and monitoring. It notes that PET scans will continue to be an important part of guiding therapy in other medical contexts, such as in the case of radioligand therapy.
“Our goal has been to take the most constrained, complex, and costly medical imaging solution in radiology and replace it with what is the most accessible, simple, and affordable, which is CT,” said Sean Walsh, RADiCAIT’s CEO. This vision is further proven by the company’s goal to expand access of industry-leading diagnostic solutions to healthcare providers across the globe.
RADiCAIT claims that its synthetically generated chemical PET images are almost indistinguishable from real, lab-created chemical PET scans. This resemblance provides a reliable surrogate for various diagnostic and prognostic uses. This advance has the potential to make a big difference in the healthcare landscape by cutting costs and making access to needed imaging services easier.
RADiCAIT’s leadership team is made up of JP Sampson, COO, Sina Shahandeh, CTO and Regent Lee, CMIO. Collectively, they are charting an exciting new course, laying out the future of medical imaging focused on quality and innovation.